An open label study to assess the effect of intravenous loading doses of bondronat [ibandronic acid] on metastatic bone pain in patients with breast cancer and skeletal metastases.

Trial Profile

An open label study to assess the effect of intravenous loading doses of bondronat [ibandronic acid] on metastatic bone pain in patients with breast cancer and skeletal metastases.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 27 Aug 2016

At a glance

  • Drugs Ibandronic acid (Primary)
  • Indications Advanced breast cancer; Cancer metastases
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 23 Aug 2016 Status changed from discontinued to withdrawn prior to enrolment.
    • 25 Mar 2008 Status changed from in progress to discontinued as reported by ClinicalTrials.gov.
    • 23 Jan 2008 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top